A GLP-1 telehealth intake should ask at least 14 questions taken from the Zepbound and Wegovy labels: measured weight, thyroid cancer or MEN 2 history, past drug reactions, pancreatitis, gallbladder and kidney disease, diabetes medicines, eye conditions, gastroparesis, pregnancy, birth control pills, surgery, depression and eating disorders.
Seven of them a form can record; seven need a clinician to follow up. Labels and FDA communications read November 21, 2026.
Takeaway: a good intake asks at least 14 questions drawn from the drug labels; seven a form can record, and seven need a clinician to follow up.
Why use the drug labels as the yardstick?
A GLP-1 telehealth intake is the only medical screening many patients get before a prescription. There is no national checklist for it, but there is an official reference: the FDA-approved prescribing information for the brand drugs. Compounded tirzepatide and semaglutide are not FDA-approved and have no label of their own; they are made with the drugs in Zepbound and Wegovy, but they are not the same products. When a clinician screens you for a compounded GLP-1, the brand labels are still the closest official statement of who should not take the drug and what needs watching.
We read the Zepbound label (tirzepatide) as indexed by FDA's openFDA service, effective August 28, 2026, and the current Wegovy label (semaglutide) from Novo Nordisk on DailyMed, effective June 18, 2026. We added FDA's November 9, 2026 safety communication on NAION, a rare optic-nerve condition, and turned each relevant section into a plain question an intake should ask. Our eating-disorder screening guide covers one item the labels do not.
The 14-question checklist
| # | Question | Label basis | Form or clinician? |
|---|---|---|---|
| 1 | What are your height and weight, and how were they measured? | Indications (section 1): adults with obesity, or with overweight and a weight-related condition | Clinician: a self-reported number needs a check (photo, scale reading or video) |
| 2 | Have you or a close relative had medullary thyroid carcinoma, or do you have MEN 2? | Boxed warning; contraindication (section 4) | Form can record it; a "yes" ends the question |
| 3 | Have you had a serious allergic reaction to semaglutide, tirzepatide or their ingredients? | Contraindication (section 4); hypersensitivity warning | Form can record it |
| 4 | Have you ever had pancreatitis? | Warnings: acute pancreatitis | Form, then clinician judgment |
| 5 | Do you have gallbladder disease or gallstones? | Warnings: acute gallbladder disease | Form can record it |
| 6 | Do you have kidney disease, or trouble keeping fluids down? | Warnings: acute kidney injury from fluid loss | Clinician: may need recent lab results |
| 7 | Do you take insulin or a sulfonylurea? | Warnings: hypoglycemia; drug interactions (section 7) | Clinician: doses may need lowering |
| 8 | Do you have diabetic retinopathy or another eye condition, or have you had sudden vision loss? | Warnings: diabetic retinopathy; FDA NAION communication, November 9, 2026 | Clinician: history and follow-up |
| 9 | Do you have severe gastroparesis or another severe stomach or bowel condition? | Zepbound warnings: severe gastrointestinal reactions ("not recommended in patients with severe gastroparesis") | Form, then clinician judgment |
| 10 | Are you pregnant, trying to conceive or breastfeeding? | Use in specific populations (section 8): discontinue when pregnancy is recognized | Form can record it |
| 11 | Do you use birth control pills? | Zepbound sections 7 and 8.3: switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase | Clinician: needs counseling |
| 12 | Do you have surgery or a procedure with sedation coming up? | Warnings: pulmonary aspiration during anesthesia or deep sedation | Form can record it; clinician advises timing |
| 13 | Have you had depression or thoughts of suicide? | No longer a label warning: both labels list the suicidal behavior and ideation section as removed in February 2026 | Clinician (good practice) |
| 14 | Have you had an eating disorder, or do you restrict food now? | Not a label item; raised by clinicians in an October 2026 CNN report | Clinician |
The last column is our own classification. "Form can record it" means a yes-or-no answer is enough to act on. "Clinician" means a good answer needs a conversation, a measurement or records: a self-reported weight, a kidney history or a medicine list cannot be judged from a checkbox. By that test, seven questions (2, 3, 4, 5, 9, 10 and 12) can be settled on a form, though a clinician should still read the answers, and seven (1, 6, 7, 8, 11, 13 and 14) need follow-up.
Which answers should stop a prescription?
Two are written as contraindications on both labels: a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and a known serious hypersensitivity to the drug or its ingredients. The boxed warning explains the first: tirzepatide and semaglutide caused thyroid C-cell tumors in rodents, and it is unknown whether they do in people. Pregnancy is handled differently but just as firmly: the Zepbound label says the drug may cause fetal harm and should be stopped when pregnancy is recognized. An intake that never asks these three things is incomplete, however quick it is.
Which answers need a clinician to follow up?
The warnings section of the Zepbound label lists ten numbered warnings; we used eight of them in the checklist, leaving out the thyroid warning (already covered by question 2) and the pen-sharing warning, which concerns the brand pen. Most of them describe conditions that change how a clinician starts or watches treatment rather than ruling it out.
Hypoglycemia is the clearest example. GLP-1s lower blood sugar, and with insulin or a sulfonylurea the label says the risk of low blood sugar rises and the other drug's dose may need to come down. That is a decision for a clinician with your medicine list, not a form. Kidney injury is another: the label ties it to fluid loss from vomiting or diarrhea, so someone with kidney disease may need recent lab results before starting.
Oral birth control matters for tirzepatide. The Zepbound label advises switching to a non-oral method, or adding a barrier method, for four weeks after starting and for four weeks after each dose increase, because the drug can reduce how well the pill is absorbed. A program that prescribes tirzepatide without mentioning this has skipped a labeled instruction.
Upcoming surgery belongs on the list because both drugs slow stomach emptying, and the Zepbound label warns of pulmonary aspiration during general anesthesia or deep sedation. Tell the clinician and the surgical team about the medicine.
What changed in 2026?
Three label developments affect the checklist. On November 9, 2026, FDA said the labels of approved GLP-1 receptor agonists must add a warning about a possible increased risk of NAION, citing 6.4 versus 3.8 cases per 100,000 person-years in its analysis of trials; FDA's communication does not mention compounded products. That makes question 8, already on the list because of diabetic retinopathy, more important: an intake should ask about eye conditions and tell you to seek care for sudden vision loss.
The Zepbound label's "Recent Major Changes" list shows the diabetic retinopathy warning updated in August 2026 and the suicidal behavior and ideation section removed in February 2026. The current Wegovy label lists the same section as removed in February 2026. Question 13 stays on the checklist as good clinical practice for a medicine that changes appetite and eating, not as a label requirement.
How do you judge the intake you just took?
Count how many of the 14 questions it asked. Programs differ in format, and the format changes what can be checked. Found says on its tirzepatide page that care on its insurance track requires a live video visit, while cash-pay care is "chat / text-based in most cases." Sunlight says its price includes unlimited video visits. NexLife's states page lists live, real-time visits in nine states and Washington, D.C., and its plan pages say only physicians with its affiliated medical group, NexLife Medical Group, prescribe. A video visit is not automatically better screening, and a written intake is not automatically worse; what matters is whether the questions were asked and whether a clinician followed up on the answers that needed it.
Use a simple score. Thirteen or fourteen questions asked, with a clinician message or call about anything you answered "yes" to, is thorough. Fewer than ten, or no human contact at all, is a reason to ask the program how it screens before you pay. Our red-flags guide lists other warning signs, and our guide to choosing an online provider covers prices and pharmacies.
Why your answers matter as much as the questions
A form can only work with what you tell it. Clinicians interviewed by CNN in October 2026 described patients with eating disorders obtaining GLP-1s online, including one who said he lied about his weight. Understating a medical history or overstating weight shifts the risk from the program to you. If a question does not fit your situation, say so in the free-text box or message the clinician before the prescription is written.
What this means for you
- Before you start, write down your height, weight, medicines (especially insulin, sulfonylureas and birth control pills), eye history and any planned surgery.
- Expect the three hard-stop questions: thyroid cancer or MEN 2 in you or your family, a past serious reaction to the drug, and pregnancy.
- If the intake skipped several checklist items, message the clinician with the answers yourself, or ask the program how it screens.
- After starting, report severe stomach pain, signs of low blood sugar or sudden vision changes promptly.
- Compounded GLP-1s are not FDA-approved, and no program can promise weight loss.
For what each program charges after the first month, see our November price-change report and the program reviews; for common effects, our tirzepatide side-effects guide.
Frequently asked questions
What should a GLP-1 telehealth intake ask?
Which answers rule out a GLP-1?
Is a questionnaire enough to prescribe a GLP-1?
Do compounded GLP-1s have their own label?
What did FDA change about GLP-1s and eye problems in 2026?
Why does birth control matter with tirzepatide?
Sources
- Zepbound (tirzepatide) prescribing information, DailyMed; openFDA version effective August 28, 2026, read November 21, 2026
- Wegovy (semaglutide) prescribing information, Novo Nordisk, DailyMed; version effective June 18, 2026
- openFDA drug label API: Zepbound, read November 21, 2026
- FDA Drug Safety Communication: GLP-1 receptor agonists and NAION, November 9, 2026, read via the portfolio news ledger November 20, 2026
- FDA: concerns with unapproved GLP-1 drugs used for weight loss (content current October 1, 2026)
- CNN: weight-loss drugs and eating disorders, October 15, 2026 (reported)
- Found: compounded tirzepatide (visit format), read November 21, 2026
- Sunlight: homepage (visits included), read November 21, 2026
- NexLife: states and visit types, read November 20, 2026 (portfolio read)